Brentuximab Vedotin for Newly Diagnosed CHL in Chinese CAYA Based on PET/CT Assessment
Status:
RECRUITING
Trial end date:
2039-11-15
Target enrollment:
Participant gender:
Summary
Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.
Phase:
PHASE2
Details
Lead Sponsor:
Children's Cancer Group, China
Collaborators:
Children's Hospital of Hebei Province Children's Hospital of Henan Province Najing Children's Hospital Qilu Hospital of Shandong University Second Affiliated Hospital of Anhui Medical University Shanghai Children's Medical Center Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The First Affiliated Hospital of Zhengzhou University Tianjin Medical University Cancer Institute and Hospital Tongji Hospital West China Second University Hospital Xiangya Hospital of Central South University